Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation reports developments as a medical technology company focused on minimally invasive treatments for severe emphysema and chronic obstructive pulmonary disease. Its commercial platform includes the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform and StratX Lung Analysis Reports, which are designed to assess and treat symptomatic severe emphysema/COPD patients. The Zephyr Valve received FDA premarket approval after breakthrough device designation and is commercially available in more than 25 countries.
Recurring Pulmonx news covers quarterly and annual financial results, U.S. and international revenue trends, gross margin, commercial execution, clinical program activity, debt refinancing, cost initiatives, inducement equity awards and governance or leadership changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Bank of America Securities 2023 Health Care Conference in Las Vegas on May 9, 2023, at 3:55 PM PT / 6:55 PM ET. The presentation will be accessible via a live and archived webcast on the company’s website.
Pulmonx is known for its Zephyr® Endobronchial Valve, which treats patients with severe emphysema/COPD. This device has received FDA pre-market approval as a breakthrough device and is available in over 25 countries. With more than 100,000 valves employed, over 25,000 patients have been treated worldwide.
Pulmonx Corporation (Nasdaq: LUNG) plans to release its financial results for Q1 2023 on Tuesday, May 2, 2023, after trading hours. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Pulmonx is recognized for its innovative treatments for lung diseases, particularly the Zephyr® Endobronchial Valve, which has received FDA pre-market approval as a breakthrough device. The company has successfully deployed over 100,000 valves to treat more than 25,000 patients globally, illustrating its significant market presence and commitment to advancing pulmonary care.
Pulmonx Corporation (LUNG) reported strong financial results for Q4 and full year 2022, achieving a record worldwide revenue of $53.7 million, an 11% increase from 2021. Q4 revenue reached $15.4 million, marking a 13% year-over-year growth. U.S. revenue for 2022 increased by 30% to $32.5 million, while international revenue saw a 10% decline to $21.2 million. The gross margin was stable at 74% for the year. Despite a net loss of $58.9 million in 2022, Pulmonx expects revenue for 2023 to rise to between $63 million and $65 million.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive lung disease treatments, will participate in a fireside chat at the Citi 2023 Healthcare Conference on March 2, 2023, at 10:15 AM PT / 1:15 PM ET. The event will be accessible via a live and archived webcast on the company’s Investors section of their website.
Pulmonx is known for its Zephyr® Endobronchial Valve and related systems used extensively in treating severe emphysema/COPD, with over 100,000 valves utilized in more than 25,000 patients worldwide.
Pulmonx Corporation (Nasdaq: LUNG) will announce its financial results for Q4 and full year 2022 on February 22, 2023, after market close. The management will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. The company focuses on minimally invasive treatments for lung diseases, including the Zephyr® Endobronchial Valve, which has been commercially available in over 25 countries and used to treat more than 25,000 patients.
Investors can access a live and archived webcast of the event on the Investors section of the Pulmonx website.
Pulmonx Corporation has partnered with the American Lung Association to enhance education on Endobronchial Valves, a treatment for severe COPD. This initiative focuses on raising awareness among patients and healthcare providers about available treatment options. The campaign aims to empower individuals living with COPD by highlighting the minimally invasive nature of Endobronchial Valves, which can significantly improve quality of life. With over 25,000 patients treated with the Zephyr Valves, this collaboration seeks to expand treatment accessibility and knowledge.